Form 6-K Cellectis S.A. For: Feb 02
- Wall St ends higher as Yellen vows actions to safeguard deposits
- Wall Street digests Powell's comments on banks, rate cuts and inflation
- PacWest says it would not be 'prudent' to go ahead with capital raise; Analyst optimistic
- Block (SQ) shares plunge after Hindenburg claims it misleads investors with 'inflated metrics'
- Coinbase Wells Notice: Oppenheimer cuts; Mizuho says a third of revenue could be affected
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February 2023
Commission File Number: 001-36891
(Exact Name of registrant as specified in its charter)
8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
|99.1||Press Release, dated February 2, 2023|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: February 2, 2023||/s/ André Choulika|
|Chief Executive Officer|
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Electra Provides Notice of Fourth Quarter 2022 Results Conference Call and Webcast
- Colonnade Acquisition Corp. II Confirms Redemption of Shares at $10.23 Per Share
- Celyad Oncology reports full year 2022 financial results and recent business highlights
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!